Dna Testing Centers Revenue Growth Rates (DNAT), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Dna Testing Centers Corp  (DNAT)
 

DNAT's Revenue Growth by Quarter and Year

Dna Testing Centers's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

DNAT Revenue (in millions $) FY 2018 FY 2017 FY 2016 FY 2015
4th Quarter December 0.00
3rd Quarter September 0.01
2nd Quarter June 0.01
1st Quarter March 0.02
FY 0.04





DNAT Revenue fourth quarter 2018 Y/Y Growth Comment
Dna Testing Centers Corp in the fourth quarter 2018 recorded of $ 0.00 millions.

According to the results reported in the fourth quarter 2018, Dna Testing Centers Corp achieved the best Revenue growth in In Vitro & In Vivo Diagnostic Substances industry. While Dna Testing Centers Corp' s Revenue meltdown of -110.47% ranks overall at the positon no. in the fourth quarter 2018.


DNAT Revenue ( Y/Y Growth %) 2018
 2017 2016 2015
4th Quarter December - - - -
3rd Quarter September 0 % 0 % 0 % -
2nd Quarter June 0 % - - -
1st Quarter March 100 % 0 % - -
FY   -24.19 % 150 % 100 % -

Financial Statements
Dna Testing Centers's fourth quarter 2018 Revenue $ 0.00 millions DNAT's Income Statement
Dna Testing Centers's fourth quarter 2017 Revenue $ 0.02 millions Quarterly DNAT's Income Statement


DNAT Revenue (Quarter on Quarter Growth %)

 2018
 2017 2016 2015
4th Quarter December - 100 % - -
3rd Quarter September 0 % 0 % - -
2nd Quarter June -50 % 0 % - -
1st Quarter March 0 % - - -
FY (Year on Year)   -24.19 % 150 % 100 % -


Back to DNAT Growth rate Comparisons >> Back to DNAT Growth rate Comparisons >>


Revenue fourth quarter 2018 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #

Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
(Jun 30 2017)   (Dec 31 2018)
Revenue fourth quarter 2018 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #
Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
(Jun 30 2017)   (Dec 31 2018)

Revenue by Quarter for the Fiscal Years 2015, 2016, 2017, 2018

Dna Testing Centers's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


DNAT's IV. Quarter Q/Q Revenue Comment
Recent accomplishment of 0.00 millions by Dna Testing Centers Corp come out even worse considering the 0.01 millions a quarter before.

Within In Vitro & In Vivo Diagnostic Substances industry Dna Testing Centers Corp achieved highest sequential Revenue growth. While Dna Testing Centers's Revenue growth quarter on quarter, overall rank is .


Revenue Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


DNAT's IV. Quarter Q/Q Revenue Comment
Recent accomplishment of 0.00 millions by Dna Testing Centers Corp come out even worse considering the 0.01 millions a quarter before.

Within In Vitro & In Vivo Diagnostic Substances industry Dna Testing Centers Corp achieved highest sequential Revenue growth. While Dna Testing Centers's Revenue growth quarter on quarter, overall rank is .


Dna Testing Centers's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2018)		 12 Months Ending
(Dec 31 2017)		 12 Months Ending
(Sep 30 2017)		 12 Months Ending
(Jun 30 2017)		 12 Months Ending
(Mar 31 2017)
Cumulative Revenue 12 Months Ending $ 0.03 $ 0.05 $ 0.06 $ 0.06 $ 0.04
Y / Y Revenue Growth (TTM) -27.46 % 56.23 % 106.16 % 178.02 % 129.62 %
Year on Year Revenue Growth Overall Ranking # 853 # 0 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) -35.75 % -9.59 % 0.16 % 24.68 % 38.38 %
Seq. Revenue Growth (TTM) Overall Ranking # 603 # 94 # 0 # 0 # 334


Cumulative Revenue growth Comment
For the 12 months ended Dec 31 2018 Dna Testing Centers reported a drop in Revenue by -27.46% year on year, to $0 millions, compare to the 56.23% growth at Dec 31 2017.

In the Healthcare sector 164 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 853.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 2
Healthcare Sector # 165
Overall # 853

Revenue TTM Y/Y Growth Statistics
High Average Low
25.15 %
 25.15 %
25.15 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 2
Sector # 134
S&P 500 # 603
Cumulative Revenue growth Comment
For the 12 months ended Dec 31 2018 Dna Testing Centers reported a drop in Revenue by -27.46% year on year, to $0 millions, compare to the 56.23% growth at Dec 31 2017.

In the Healthcare sector 164 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 853.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 2
Healthcare Sector # 165
Overall # 853

Revenue TTM Y/Y Growth Statistics
High Average Low
25.15 %
25.15 %
25.15 %
 






Other Revenue Growth
In Vitro & In Vivo Diagnostic Substances Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
DNAT's Revenue Growth Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Dec 31 2018 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2018
Zimmer Biomet Holdings Inc -0.16%$ -0.159 millions
Tg Therapeutics Inc -0.25%$ -0.249 millions
Hanger inc.-0.31%$ -0.309 millions
Surgalign Holdings Inc -0.55%$ -0.546 millions
3m Company-0.56%$ -0.563 millions
Bio rad Laboratories Inc -0.72%$ -0.717 millions
Quest Diagnostics Inc-1.39%$ -1.394 millions
Biomarin Pharmaceutical Inc-1.42%$ -1.421 millions
Inspiremd Inc -1.44%$ -1.439 millions
Star Equity Holdings Inc -1.46%$ -1.459 millions
Prophase Labs Inc -1.47%$ -1.470 millions
Meridian Bioscience Inc -1.54%$ -1.536 millions
Sonida Senior Living Inc -1.60%$ -1.601 millions
Hca Healthcare Inc -1.78%$ -1.784 millions
Immune Design Corp.-1.86%$ -1.856 millions
Bausch Health Companies Inc -1.94%$ -1.942 millions
Opiant Pharmaceuticals Inc -2.21%$ -2.211 millions
Htg Molecular Diagnostics Inc-2.23%$ -2.227 millions
Invacare Holdings Corporation-2.31%$ -2.307 millions
Pediatrix Medical Group Inc -2.46%$ -2.458 millions
Gilead Sciences Inc -2.59%$ -2.589 millions
Dentsply Sirona Inc -2.87%$ -2.869 millions
Diversicare Healthcare Services Inc -3.26%$ -3.258 millions
Encision Inc -3.33%$ -3.326 millions
Orasure Technologies Inc-3.43%$ -3.425 millions
Alphatec Holdings Inc -3.58%$ -3.576 millions
Stereotaxis Inc -3.81%$ -3.806 millions
Sophiris Bio Inc.-3.85%$ -3.846 millions
Kaya Holdings Inc -4.21%$ -4.206 millions
Utah Medical Products Inc-4.36%$ -4.362 millions


About Dna Testing Centers Revenue Growth Rates (DNAT), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.